The Medical Letter
@themedicalletter.bsky.social
A nonprofit organization that has provided independent reviews of drugs and therapeutics since 1959. Funded solely by subscriptions and donations. Because the source matters.
Answer: d
Rash and mild injection-site reactions have also occurred. Very low LDL-C levels due to PCSK9 inhibitor use have not been associated with adverse clinical effects.
Rash and mild injection-site reactions have also occurred. Very low LDL-C levels due to PCSK9 inhibitor use have not been associated with adverse clinical effects.
January 13, 2026 at 6:26 PM
Answer: d
Rash and mild injection-site reactions have also occurred. Very low LDL-C levels due to PCSK9 inhibitor use have not been associated with adverse clinical effects.
Rash and mild injection-site reactions have also occurred. Very low LDL-C levels due to PCSK9 inhibitor use have not been associated with adverse clinical effects.
Answer: a
in adults with heart failure (reduced or preserved ejection fraction), an SGLT2 inhibitor is recommended. In those with symptomatic heart failure with preserved ejection fraction and obesity, a GLP-1 receptor agonist is recommended.
in adults with heart failure (reduced or preserved ejection fraction), an SGLT2 inhibitor is recommended. In those with symptomatic heart failure with preserved ejection fraction and obesity, a GLP-1 receptor agonist is recommended.
December 16, 2025 at 10:33 PM
Answer: a
in adults with heart failure (reduced or preserved ejection fraction), an SGLT2 inhibitor is recommended. In those with symptomatic heart failure with preserved ejection fraction and obesity, a GLP-1 receptor agonist is recommended.
in adults with heart failure (reduced or preserved ejection fraction), an SGLT2 inhibitor is recommended. In those with symptomatic heart failure with preserved ejection fraction and obesity, a GLP-1 receptor agonist is recommended.
Answer: d
Screening is also recommended in hypertensive patients with resistant disease, an incidentally discovered adrenal mass, or a family history of early-onset hypertension or stroke.
Screening is also recommended in hypertensive patients with resistant disease, an incidentally discovered adrenal mass, or a family history of early-onset hypertension or stroke.
November 25, 2025 at 7:00 PM
Answer: d
Screening is also recommended in hypertensive patients with resistant disease, an incidentally discovered adrenal mass, or a family history of early-onset hypertension or stroke.
Screening is also recommended in hypertensive patients with resistant disease, an incidentally discovered adrenal mass, or a family history of early-onset hypertension or stroke.